
1. j trop med hyg. 2017 sep;97(3):702-711. doi: 10.4269/ajtmh.16-0779. epub 2017 
jul 27.

hemolytic potential tafenoquine female volunteers heterozygous for
glucose-6-phosphate dehydrogenase (g6pd) deficiency (g6pd mahidol variant) versus
g6pd-normal volunteers.

rueangweerayut r(1), bancone g(2), harrell ej(3), beelen ap(4), kongpatanakul
s(5), möhrle jj(6), rousell v(3), mohamed k(3), qureshi a(3), narayan s(3), yubon
n(7), miller a(8), nosten fh(2), luzzatto l(9)(10), duparc s(6), kleim jp(3),
green ja(3).

author information: 
(1)department internal medicine, mae sot general hospital, mae sot, thailand.
(2)shoklo malaria research unit, mahidol-oxford tropical medicine research unit, 
faculty tropical medicine, mahidol university, mae sot, thailand.
(3)glaxosmithkline research development ltd., uxbridge, united kingdom.
(4)glaxosmithkline, research triangle park, north carolina.
(5)faculty medicine, siriraj hospital, mahidol university, bangkok, thailand.
(6)medicines malaria venture, geneva, switzerland.
(7)glaxosmithkline, bangkok, thailand.
(8)glaxosmithkline, king prussia, pennsylvania.
(9)department hematology blood transfusion, muhimbili university health
and allied sciences, dar-es-salaam, tanzania.
(10)istituto toscano tumori, florence, italy.

tafenoquine 8-aminoquinoline investigation prevention of
relapse plasmodium vivax malaria. open-label, dose-escalation study
assessed quantitatively hemolytic risk tafenoquine female healthy
volunteers heterozygous mahidol487a glucose-6-phosphate dehydrogenase
(g6pd)-deficient variant versus g6pd-normal females, reference to
primaquine. six g6pd-heterozygous subjects (g6pd enzyme activity 40-60% of
normal) six g6pd-normal subjects per treatment group received single-dose
tafenoquine (100, 200, 300 mg) primaquine (15 mg × 14 days). all
participants pretreatment hemoglobin levels ≥ 12.0 g/dl. tafenoquine dose
escalation stopped hemoglobin decreased ≥ 2.5 g/dl (or hematocrit decline
≥ 7.5%) versus pretreatment values ≥ 3/6 subjects. dose-response evident
in g6pd-heterozygous subjects (n = 15) receiving tafenoquine maximum
decrease hemoglobin versus pretreatment values. hemoglobin declines were
similar tafenoquine 300 mg (-2.65 -2.95 g/dl [n = 3]) primaquine
(-1.25 -3.0 g/dl [n = 5]). two cohorts g6pd-heterozygous subjects
with g6pd enzyme levels 61-80% (n = 2) > 80% (n = 5) site median
normal received tafenoquine 200 mg; hemolysis less pronounced higher g6pd 
enzyme activities. tafenoquine hemolytic potential dose dependent, and
hemolysis greater g6pd-heterozygous females lower g6pd enzyme
activity levels. single-dose tafenoquine 300 mg appear increase the
severity hemolysis versus primaquine 15 mg × 14 days.

doi: 10.4269/ajtmh.16-0779 
pmcid: pmc5590573
pmid: 28749773  [indexed medline]

